Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 615.40 INR
Change Today +4.45 / 0.73%
Volume 2.5M
As of 7:05 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

cipla ltd (CIPLA) Snapshot

Open
607.20
Previous Close
610.95
Day High
618.20
Day Low
606.50
52 Week High
03/10/15 - 752.85
52 Week Low
07/10/14 - 425.25
Market Cap
494.2B
Average Volume 10 Days
2.2M
EPS TTM
14.71
Shares Outstanding
803.1M
EX-Date
08/11/15
P/E TM
41.8x
Dividend
2.00
Dividend Yield
0.32%
Current Stock Chart for CIPLA LTD (CIPLA)

Related News

No related news articles were found.

cipla ltd (CIPLA) Related Businessweek News

No Related Businessweek News Found

cipla ltd (CIPLA) Details

Cipla Limited manufactures and sells pharmaceutical and personal care products in India and internationally. The company offers active pharmaceutical ingredients; and formulations in therapeutic areas, such as allergy, analgesic, anti malarial, anti-infectives, cardiology, dermatology and cosmeceuticals, diabetology, gastroenterology, HIV-AIDS, hormones and steroids, iron chelators, musculoskeletal, neuropsychiatry, nutritional and ophthalmic products, oncology, respiratory, urology, and women’s health, as well as steroids and hormones. It also provides veterinary products for various animals, including companion, equine, general care, live stock, and poultry. In addition, the company offers inhaled medication and devices comprising metered dose inhalers with dose indicators, dry powder inhalers, nasal sprays, nebulisers, non-electrostatic spacers, and infant and baby masks. It exports raw materials, intermediates, prescription drugs, OTC drugs, and veterinary products to approximately 170 countries worldwide. Cipla Limited was founded in 1935 and is based in Mumbai, India.

Founded in 1935

cipla ltd (CIPLA) Top Compensated Officers

Managing Director, Global Chief Executive Off...
Total Annual Compensation: 137.5M
Whole-Time Director, Member of Mergers & Acqu...
Total Annual Compensation: 12.0M
Compensation as of Fiscal Year 2014.

cipla ltd (CIPLA) Key Developments

Cipla and Bristol-Myers Squibb Settle Hepatitis B Drug Dispute Out of Court

The patent dispute between Bristol-Myers Squibb (BMS) and Cipla over Entecavir, a combination for treating Hepatitis B, has been settled amicably out of court. The Intellectual Property Appellate Board (IPAB), taking into consideration the endorsement by the warring parties, dismissed the original rectification application filed by Cipla against BMS' patent. The counsels appearing for both the parties informed the IPAB that the matter has been settled out of court in April, 2015. The IPAB bench comprising Justice KN Basha and DPS Parmar, technical member - patent dismissed the application as withdrawn not pressed. The companies requested the terms of settlement has to be kept confidential.

Cipla Ltd. Plans to Co-Invest With Government In Health Sector but Doesn’t Intend to Sell Stake

Subhanu Saxena, Chief Managing Director at Cipla Limited (NYSEI:CIPLA) said,” We can co-invest with the government to change the healthcare approach, as well as achieve our objective of putting patients first. With practically no debt, and a cash-pile of INR 10 billion, the company will look at acquisitions, mainly brands only, if they come at the right price”. “We have more opportunities than we can execute”, he said, adding that the company has no plans to sell stake.

Cipla Seeks Acquisitions

Cipla Limited (NSEI:CIPLA) will consider acquisitions. With practically no debt, and a cash-pile of INR 10 billion, Cipla will look at acquisitions, mainly brands only, if they come at the "right price.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CIPLA:IN 615.40 INR +4.45

CIPLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 1,452 INR +48.70
Cadila Healthcare Ltd 1,797 INR +81.00
Divi's Laboratories Ltd 1,880 INR +46.85
Piramal Enterprises Ltd 928.05 INR -3.50
Torrent Pharmaceuticals Ltd 1,301 INR +7.45
View Industry Companies
 

Industry Analysis

CIPLA

Industry Average

Valuation CIPLA Industry Range
Price/Earnings 41.2x
Price/Sales 4.5x
Price/Book 4.5x
Price/Cash Flow 28.8x
TEV/Sales 4.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CIPLA LTD, please visit www.cipla.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.